How to Get Mass Tort Clients in 2026: Costs, Benchmarks and Strategy

The Real Opportunity in Mass Tort Client Acquisition Right Now

Knowing how to get mass tort clients efficiently is one of the highest-leverage decisions a plaintiff firm makes, because case acquisition cost directly determines whether a docket is profitable before a single settlement closes. Active MDLs, emerging tort inventories, and a paid media landscape that still rewards disciplined spend have created real margin opportunities for firms that approach intake as a data problem. The firms capturing those opportunities are building systematic acquisition programs, not running one-off campaigns and hoping volume follows.

Right now the market is active. There are live MDLs with favorable bellwether results, emerging torts with early claimant pools that have not been saturated by competitors, and a paid advertising environment on Facebook and Google that still rewards firms willing to spend with discipline and data. If your firm is not aggressively solving the client acquisition problem, a competitor down the street is, and they are signing the cases you should have.

What Mass Torts Actually Are, and Why Individual Claims Matter to Your Economics

Before getting into acquisition strategy, it is worth being precise about the structure, because the structure drives the economics of signing each client.

A mass tort is a civil action where a large number of individual plaintiffs have claims against one or a small number of defendants, typically over defective products or harmful pharmaceuticals. Unlike a class action lawsuit, where a single judgment or settlement applies to the entire class and individual compensation is often nominal, mass tort cases preserve the individual claim. Each plaintiff keeps their own case. Compensation is determined based on that plaintiff's specific injuries, exposure, and damages. That distinction is everything from a firm's perspective, because it means the value of each signed case is tied to individual facts, not averaged down across thousands of people.

In practice, mass torts are usually coordinated in a Multidistrict Litigation (MDL) at the federal level, or through a coordinated proceeding in state court. The MDL consolidates discovery and pretrial proceedings, which dramatically reduces per-case costs for plaintiffs' firms. When a global settlement is negotiated, each plaintiff's compensation is calculated through a settlement matrix or grid that weights factors like diagnosis severity, duration of use, age, and other individual criteria. The better your intake captured those facts at the beginning, the stronger your position in the settlement allocation process.

The Economics: What "Good" Actually Looks Like

Firms that succeed at scale are running on known numbers. Before you spend a dollar on marketing, you need benchmarks for three things: cost per lead, cost per signed case, and projected case value at settlement.

Cost per lead in mass torts varies enormously by case type and channel. On Facebook, a soft lead (name, phone, email, basic qualification) in an active tort might run $50 to $250. A fully screened, signed retainer from a direct-to-consumer digital campaign can cost anywhere from $800 to $5,000 or more depending on how competitive the space is and how tight the qualifying criteria are. Case aggregators and lead vendors can appear cheaper on the surface, but the quality varies wildly and re-qualification rates can destroy your apparent cost efficiency.

The math that matters is cost per signed case against expected net recovery per case. If a tort is settling at an average of $150,000 per case and your firm's contingency is 33%, you are looking at $50,000 gross per case before expenses. If you paid $2,500 to acquire and sign that case, your acquisition cost is 5% of gross revenue. That is a business. If you paid $2,500 but your intake team is re-qualifying only 30% of leads, your real cost per signed case is north of $8,000, and the math gets uncomfortable fast.

Good looks like a signed-case acquisition cost under 10% of expected gross recovery, a lead-to-sign conversion rate above 25% for qualified leads, and an intake process that captures the documentation needed to support maximum compensation from day one.

How to Get Mass Tort Clients: The Execution Playbook

Understanding how to get mass tort clients at scale requires thinking in channels, not campaigns. No single channel fills a large docket by itself.

Paid Digital Advertising

Facebook remains the highest-volume channel for mass tort client acquisition. The platform's targeting depth, its ability to reach older demographics who are most likely to have used harmful pharmaceuticals or defective products, and its creative flexibility make it the engine of most large dockets. Google search captures intent-driven demand, particularly for claimants who have already heard about a tort and are actively searching for legal representation. YouTube is underutilized and increasingly cost-effective for video-heavy torts where a patient story builds the connection that drives a call.

The mistake most firms make is running these channels without a feedback loop. You need signed-case data flowing back to your ad platform so you are optimizing toward actual clients, not just leads. At MTAA, we have managed more than $250 million in Facebook ad spend across 600-plus plaintiff firms and 100-plus torts. The firms that consistently outperform are the ones that close the loop between intake outcomes and media buying decisions.

Referral Networks and Co-Counsel Arrangements

For firms that do not want to run paid campaigns in-house, co-counsel and referral relationships are an efficient path into a tort. If you have a strong general practice or personal injury client base, mining that database for current or former clients who used a pharmaceutical or product at issue in an active tort can generate signed cases at very low acquisition cost. Case aggregators pool cases from smaller firms and offer them to larger ones under a fee-sharing arrangement. This works, but you need to understand who originally acquired the case and under what conditions, because intake quality from aggregators is inconsistent and the ethical implications of the referral arrangement have to be structured correctly under your state's bar rules.

Efficient Intake and Lead Screening

This is where a lot of firms lose money they think they made on advertising. High-volume mass tort intake has to be built for speed and accuracy simultaneously. A lead that sits for more than five minutes has a dramatically lower contact rate. Most firms are not set up to respond in five minutes at the volume a real paid campaign generates, which is why AI-assisted intake tools and automated SMS outreach have become standard practice in serious mass tort shops. The AI angle here is real and practical. Firms using AI to handle first-touch outreach, pre-qualification questions, and document collection are converting more leads into signed cases at lower per-case cost. If you want a deeper look at how AI fits into plaintiff firm operations, the book "A Lawyer's Guide to AI" covers this in practical terms built specifically for law firms.

Pitfalls and Compliance: What Trips Firms Up

The three most common ways firms damage themselves in mass tort marketing are bar rule violations, TCPA and CIPA exposure, and wasted spend on bad lead sources.

State bar advertising rules vary significantly and some require pre-approval of attorney advertising, specific disclaimers, or restrict certain types of claims about outcomes. Before running any campaign, your advertising materials need review against the rules of every state where you are soliciting clients.

TCPA and CIPA liability from automated text and call campaigns has generated significant litigation against law firms and lead vendors alike. If you are buying leads from a vendor who obtained consent through a third-party form that listed 50 other advertisers, that consent may not hold up. Your exposure is real. Get counsel on your intake communication sequences before you scale.

Wasted spend on lead vendors is the quietest budget killer. Some vendors sell the same lead to five or more firms simultaneously. By the time your intake team calls, the potential client has already signed with someone else. Exclusivity, lead age, and source transparency are non-negotiable terms to demand from any vendor relationship.

How MTAA Approaches This for Plaintiff Firms

MTAA works on a transparent cost-plus model: firms pay actual ad spend plus a 15% management fee, with no hidden markups on media. That structure matters because it aligns our incentives with the firm's. We are not incented to run inefficient spend. Our focus is on driving down cost per signed case, which is the only number that affects the firm's profitability.

With experience across 100-plus torts and $250 million-plus in managed spend, we have seen what works at every stage of a tort's lifecycle, from the early market before CPLs spike, through the competitive peak, to the late-stage push before MDL settlement. Timing your ad investment to the tort's litigation stage is one of the most underappreciated decisions in case acquisition strategy.

Closing: Building a Repeatable System for Mass Tort Client Acquisition

Knowing how to get mass tort clients is not about finding one great campaign or one good vendor. It is about building a system: paid media that optimizes toward signed cases, intake infrastructure that converts at high rates, referral and co-counsel relationships that add volume without sacrificing quality, and compliance practices that protect the firm from the liability that comes with scale. The firms that crack that system get compounding returns as their data improves and their processes tighten. For any plaintiff firm serious about how to get mass tort clients consistently and profitably, the investment in building that system is the most important business decision on the table right now.